Search clinical trials for: PF-07038124 or vehicle

Total 64 results

Pfizer

Completed

A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants

Dermatitis Atopic

United States
Pfizer

Completed

Study to Evaluate the Safety, Local and Systemic Tolerability, and Pharmacokinetics of Multiple-Dose Topical Administration of PF-07038124 in Japanese Healthy Participants

Healthy

Japan
Pfizer

Completed

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Plaque Psoriasis | Atopic Dermatitis

United States, Canada, United Kingdom, Japan
Pfizer

Completed

Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis (EMPORIA)

Plaque Psoriasis | Atopic Dermatitis

United States, Australia, Canada, Poland
Icahn School of Medicine at Mount Sinai
Pfizer

Recruiting

PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea

Seborrheic Dermatitis | Papulopustular Rosacea

United States
University of Colorado, Denver
Pfizer

Active, not recruiting

Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo

Vitiligo

United States
Pfizer

Terminated

A Single Dose Study Of PF-06291874 In Healthy Adult Subjects

Healthy

United States
Bausch & Lomb Incorporated

Completed

A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.

Primary Open Angle Glaucoma | Ocular Hypertension

Japan
Pfizer

Completed

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

Psoriasis

Canada, United States, Japan, Poland
Bausch & Lomb Incorporated
NicOx Inc.

Completed

Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

Primary Open Angle Glaucoma | Ocular Hypertension | Pigmentary Glaucoma | Pseudoexfoliative Glaucoma

United States
Pfizer

Completed

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

Ocular Hypertension | Primary Open-Angle Glaucoma

United States
Pfizer

Completed

A Single Dose Study Of PF-05161704 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer

Withdrawn

A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects

Obesity
Pfizer

Completed

A Study Of PF-05175157 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer

Terminated

A Multiple Dose Study Of PF-05161704 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects

Healthy Volunteers

Belgium
Pfizer

Completed

A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

United States
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Completed

A First-in-Human Study of QY101 Ointment in Adult Subjects

Healthy Volunteer

China
Leadiant Biosciences, Inc.

Completed

Safety and Tolerability of STP206 in Healthy Adult Subjects

Healthy

United States
Pfizer

Not yet recruiting

A Study to Learn About the Study Medicine Called PF-07054894 in People of Japanese Origin

Healthy

Belgium
Pfizer

Terminated

A Single Oral Dose Study Of PF-06409577 In Healthy Adult Subjects

Healthy

Belgium
Pfizer

Terminated

A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

A Study Of PF-04620110 As A Modified-Release Formulation In Healthy Overweight Or Obese Subjects

Healthy

Belgium
Pfizer

Completed

A Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-03882845 In Healthy Volunteers

Healthy Volunteers

United States
Pfizer
Pfizer

Recruiting

A Phase 2/3 Study in Adult and Pediatric Participants With SCD

Sickle Cell Disease

United States, Nigeria, Kenya, Lebanon
Pfizer

Completed

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Spain, Israel, Korea, Republic of, Russian Federation, Turkey, Czechia, Hungary, Italy, Poland, Bulgaria, Denmark, Germany, Serbia, Austria, Slovakia, Ukraine, Georgia, Romania
Mylan Inc.
Vyne Therapeutics Inc.; DPT Laboratories, Ltd.

Completed

A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies

Scabies

United States, Dominican Republic, Honduras, Puerto Rico
OcuNexus Therapeutics, Inc.

Completed

A Study to Assess the Safety, Tolerability and Effect of Nexagon™ Applied to the Eye After PRK Laser Eye Surgery for Nearsightedness

Corneal re-Epithelialization

New Zealand
OcuNexus Therapeutics, Inc.

Completed

A Study Evaluating Nexagon™ in the Treatment of Skin Wounds.

Wound Healing

New Zealand
Pfizer

Completed

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

Healthy Participants

United States, Belgium
Pfizer

Terminated

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

Prostatic Neoplasms

United States
Pfizer

Completed

Safety and Pharmacokinetic Study of PF-06651600 in Healthy Volunteers

Healthy

Belgium
Pfizer

Completed

A Single Dose Study Of PF-06678552 In Healthy Subjects

Healthy

Belgium
Pfizer

Completed

A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Oral Doses Of PF-06273340

PAIN

Belgium
Pfizer

Terminated

A Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 In Japanese Healthy Adult Volunteers

Healthy Volunteers

United States
Pfizer

Completed

A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329

Ocular Hypertension | Glaucoma, Open-Angle

United States
Omeros Corporation

Terminated

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

IgA Nephropathy

United States, Argentina, Australia, Belgium, Bulgaria, Canada, Czechia, Germany, Greece, Hungary, India, Italy, Korea, Republic of, Lithuania, Poland, Singapore, Slovakia, Spain, Sweden, Taiwan, Thailand, Turkey, United Kingdom
Pfizer

Completed

Evaluation of Skin Irritation Potential With PF-06700841 Cream Formulation Using Negative Control in Adult Japanese Healthy Participants

Healthy

Japan
Pfizer

Completed

Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis

Psoriasis

United States, Germany, Canada, Denmark, Hungary, Australia, Latvia, Poland, Bulgaria, Japan
Pfizer

Completed

Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

Atopic Dermatitis

Germany, United States, Canada, Denmark, Hungary, Australia, Latvia, Poland, Bulgaria, Japan
Pfizer

Completed

A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01)

Healthy

United States
Pfizer

Completed

A First In Human Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Single Oral Doses Of PF-06372865

Healthy

Netherlands
Cedars-Sinai Medical Center

Withdrawn

REgenerative CardiOsphere iNjection to STRengthen dysfUnCTional Hearts (RECONSTRUCT)

Ischemic Cardiomyopathy | Chronic Ischemic Cardiomyopathy

United States
Pfizer
Kyowa Kirin Co., Ltd.

Terminated

A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors

Advanced/Metastatic Solid Tumors

United States
Novan, Inc.
Spaulding Clinical Research LLC

Completed

A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204

Acne Vulgaris

United States
Pharma Holdings AS
CTC Clinical Trial Consultants AB

Completed

Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus

Nasal Decolonization of Staphylococcus Aureus

Sweden
Pfizer

Completed

Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Pierre Fabre Medicament

Active, not recruiting

Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer (OCEANII)

Non-Small Cell Lung Cancer

China, Taiwan
Pfizer

Completed

Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis

Psoriasis

Germany
University of South Florida

Completed

Efficacy and Safety of Filgrastim in Alzheimer's Disease (FFAD)

Alzheimer's Disease

United States

3

Subscribe